Table 1.
List of criteria for assessing the methodological quality of studies on patient-reported outcomes among patients with cancer and diabetes
| Positive if with respect to | Number of studies that scored positive |
|---|---|
| Patient-reported outcomes | N (%) |
| 1. Examining PROs was a primary objective of the study | 10 (100) |
| 2. A validated questionnaire to measure PROs was used | 10 (100) |
| Study population | |
| 3. The patient sampling process is described | 10 (100) |
| 4. A (healthy) normative sample is included for comparison | 3 (30) |
| 5. Patients with both cancer and diabetes are compared to either patients with only cancer or only diabetes on at least two sociodemographic variables | 8 (80) |
| 6. A description is included of at least two clinical variables regarding cancer diagnosis (e.g., cancer stage, treatment, time since cancer diagnosis) | 8 (80) |
| 7. A description is included of at least two clinical variables regarding diabetes diagnosis or severity (e.g., HbA1c levels, treatment, time since diabetes diagnosis) | 3 (30) |
| 8. Inclusion and/or exclusion criteria are described | 9 (90) |
| 9. Participation rates for patient groups are described and these are >75 % | 4 (40) |
| 10. Information is given regarding differences in demographic and/or clinical characteristics of respondents vs non-respondents | 3 (30) |
| Study design | |
| 11. The study sample includes at least 75 patients (arbitrarily chosen) | 8 (80) |
| 12. The process of data collection is described | 8 (80) |
| 13. The difference in the outcome variable between cancer patients with diabetes and patients with only cancer and/or only diabetes is assessed in multivariable models, including at least 2 covariates | 8 (80) |
| Results | |
| 14. Mean, median, standard deviations, or percentages are reported and compared between cancer patients with diabetes and patients with only cancer and/or only diabetes for the most important outcome measures | 8 (80) |